NMPA holds meetings on vaccine regulatory QMS

The National Medical Products Administration (NMPA) held meetings on the construction of the vaccine regulatory quality management system (QMS) in Nanjing, Jiangsu province, and Urumqi, Xinjiang Uygur autonomous region, on May 16 and May 30, respectively, in a bid to enhance the construction of the QMS and facilitate the cohesion and coordination of the QMS in the vaccine regulatory system.

The meetings briefed on the construction and operation of the NMPA's QMS, and introduced the NMPA's experience in its internal control system, vaccine registration and marketing authorization quality management, internal audit, and service object satisfaction survey.

At the meetings, the NMPA’s National Institute for Food and Drug Control, the Center for Food and Drug Inspection and the Center for Medical Device Evaluation respectively presented the progress made in ensuring the consistency of vaccine lot release network laboratories, the construction of the QMS for drug inspection, and the construction and operation of the QMS for technical review of medical products.

The provincial medical products administrations of Jiangsu and Xinjiang respectively shared information on the operation of the provincial-level vaccine regulatory QMS.

Local drug regulatory authorities in attendance exchanged views on the construction, operation and promotion of the QMS, shared experience and successful practices and put forward suggestions on further advancing the construction of the QMS.

Officials of related departments of the NMPA and personnel of local drug regulatory authorities in charge of quality management also participated in the meetings.